Patent ID: 11911458
Assignee: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 16:
17. A method of treating HIV infection in a subject, the method comprising:
(a) immunizing the subject with an effective amount of an HIV vaccine;
(b) purifying peripheral blood mononuclear cells (PBMC) isolated from the subject;
(c) positively selecting HIV-specific CD4+ T cells from the PBMC;
(d) contacting the HIV-specific CD4+ T cells ex vivo with a therapeutically effective amount of a second stimulatory agent,
wherein the second stimulatory agent comprises a peptide, a mixture of peptides, or a vaccine;
(e) transducing the HIV-specific CD4+ T cells ex vivo with a viral delivery system encoding at least one genetic element,
wherein the at least one genetic element comprises (i) a sequence having at least 90% sequence identity with SEQ ID NO: 6, (ii) a sequence having at least 90% sequence identity with SEQ ID NO: 7, and (iii) a sequence having at least 90% sequence identity with SEQ ID NO: 97, wherein the at least one genetic element does not comprise any small RNA targeting HIV sequences other than Vif and Tat; and
(f) culturing the transduced HIV-specific CD4+ T cells for at least 1 day; and
(q) infusing the transduced HIV-specific CD4+ T-cells into the subject.